Individualized asparaginase dosing in childhood acute lymphoblastic leukemia

Robin Q.H. Kloos, Rob Pieters, Florine M.V. Jumelet, Hester A. De Groot-Kruseman, Cor Van Den Bos, Inge M. Van Der Sluis

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

58 Citaten (Scopus)


PURPOSE In the DCOG ALL-11 protocol, polyethylene glycol-conjugated Escherichia coli asparaginase (PEGasparaginase) and Erwinia asparaginase treatment of pediatric acute lymphoblastic leukemia are individualized with therapeutic drug monitoring (TDM). The efficacy of TDM and its effect on asparaginaseassociated toxicity are reported. PATIENTS AND METHODS After induction with 3 fixed intravenous doses of 1,500 IU/m2 PEGasparaginase, medium-risk patients (n = 243) received 14 individualized doses that targeted trough levels of 100-250 IU/L, standard-risk patients (n = 108) received 1 individualized dose, and high-risk patients (n = 18) received 2-5 fixed administrations (1,500 IU/m2). After a neutralizing hypersensitivity reaction, patients were started with 20,000 IU/m2 Erwinia asparaginase 3 times per week, and L-asparagine was measured to monitor asparaginase efficacy. Several asparaginase-associated toxicities were studied. RESULTS The final median PEGasparaginase dose was lowered to 450 IU/m2. Overall, 97% of all trough levels of nonallergic patients were >100 IU/L. Asparagine was <0.5 μM in 96% and 67% of the PEGasparaginase and Erwinia asparaginase levels >100 IU/L, respectively. Ten percent developed a neutralizing hypersensitivity reaction to PEGasparaginase, of which 40% were silent inactivations. The cumulative incidence of grade 3-4 pancreatitis, central neurotoxicity, and thromboses was 12%, 4%, and 6%, respectively, and not associated with asparaginase activity levels. During medium-risk intensification, 50% had increased ALT and 3% hyperbilirubinemia (both grade 3/4 and correlated with asparaginase activity levels), and 37% had grade 3/4 hypertriglyceridemia. Hypertriglyceridemia occurred less in intensification compared with ALL-10 (37% v 47%), which is similar to ALL-11 but with higher asparaginase levels during intensification. CONCLUSION TDM of asparaginase results in a significant reduction of the PEGasparaginase dose with adequate asparaginase activity levels and sufficient asparagine depletion. In addition, with TDM, silent inactivation and allergic-like reactions were identified. However, the effect of reduced asparaginase activity levels on toxicity is limited.

Originele taal-2Engels
Pagina's (van-tot)715-724
Aantal pagina's10
TijdschriftJournal of Clinical Oncology
Nummer van het tijdschrift7
StatusGepubliceerd - 1 mrt. 2020


Duik in de onderzoeksthema's van 'Individualized asparaginase dosing in childhood acute lymphoblastic leukemia'. Samen vormen ze een unieke vingerafdruk.

Citeer dit